干扰素信号通路对病毒性肝炎抗病毒疗效的影响

doi:10.3969/j.issn.1672-5069.2016.03.002

Abstract

Wu Wenyu,Han Meifang. Impact of interferon signal tunnel on antiviral efficacy of patients with viral hepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 261-263.

[1] Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol，2008，18（11）:545-551.
[2] Darnell JJ，Kerr IM，Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science，1994. 264（5164）:1415-1421.
[3] 黄琴. 人MxA基因重组真核载体抗乙型肝炎病毒作用的实验室研究. 重庆医科大学学报，2010，35（1）:46-48.
[4] Tur-Kaspa R. Alpha interferon suppresses hepatitis B virus enhancer activity and reduces viral gene transcription. J Virol，1990，64（4）:1821-1824.
[5] Kim EK，Choi E. Compromised MAPK signaling in human diseases:an update. Arch Toxicol，2015，89（6）:867-882.
[6] 李小玮，陈泽婷，智绪亭. IFN-α诱导的信号传导通路的研究进展. 中国现代普通外科进展，2012. 15（7）:548-551.
[7] Uddin S. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem，2000，275（36）:27634-27640.
[8] Mayer IA. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem，2001，276（30）:28570-28577.
[9] Wang WH. Sustained activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase pathways by hepatitis B virus X protein mediates apoptosis via induction of Fas/FasL and tumor necrosis factor（TNF） receptor 1/TNF-expression. Mol Cell Biol，2004，24（23）: 10352-10365.
[10] Chang WW. Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell:the antiviral role of nitric oxide. J Viral Hepat，2008，15（7）: 490-497.
[11] Fingar DC，Blenis J. Target of rapamycin （TOR）:an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene，2004，23（18）:3151-3171.
[12] Kaur S. Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol，2008，181（10）:7316-7323.
[13] Kaur S. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem，2007，282（3）:1757-1768.
[14] 黄育红，张磊.慢性乙型肝炎抗病毒治疗的最新进展. 医学综述，2014， 2014（23）:4308-4310.
[15] Sarasin-Filipowicz M. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A，2008，105（19）:7034-7039.
[16] King JK. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients:A pilot study. Hepatology，2002，36（6）:1416-1424.
[17] Knapp S. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection:roles of MxA，OAS-1 and PKR. Genes Immun，2003，4（6）:411-419.
[18] Antonelli G. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res，1999，19（3）:243-251.
[19] 樊娟. SOCS和IFN对JAK/STAT活化的影响和意义. 国际免疫学杂志，2008. 31（4）:311-313.
[20] Piganis RA. Suppressor of cytokine signaling （SOCS） 1 inhibits type I interferon（IFN） signaling via the interferon alpha receptor （IFNAR1）-associated tyrosine kinase Tyk2. J Biol Chem，2011，286（39）:33811-33818.
[21] Tseng KC. SOCS-1 promoter methylation and treatment response in chronic hepatitis C patients receiving pegylated-interferon/ribavirin. J Clin Immunol，2013，33（6）:110-116.
[22] Han MF，Li Y，Wu WY，et al. Altered expression of STAT1， MX and SOCS3 associated with outcome of therapy in HBV infection. APASL，Tokyo Japan，2016.2. 20-24.

Impact of interferon signal tunnel on antiviral efficacy of patients with viral hepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[2]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[3]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[4]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.
[5]	Yang Min, Lu Mingqin. Diagnosis and treatment of hepatocellular jaundice [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 160-162.
[6]	Duan Junmin, Li Susen, Liu Lizhen, et al. Comparison of efficacy of peginterferon α-2a and interferon α-2b combined with ribavirin in treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 64-67.
[7]	Chen Congxin，Zou Guizhou.. Do we finally find a way to eradicate hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 532-532.
[8]	Na Li.. IL-28B genotype polymorphism and its impact on sustained viral response in patients with chronic hepatitis C receiving standardized antiviral therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 600-601.
[9]	Ren Jinqing, Xu Liang, Zhang Jianqiong, et al.. Correlation between the liver function index and blood lipids in patients with acute viral hepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 38-41.
[10]	Chen Min, Li Yani, Liu Xiaolei.. Quality of domestic mainstream liver disease management mobile applications [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 42-45.
[11]	Feng Xiaoxia，Nie Yuanxia，Liang Hailin.. Impact of Yiqi Jiedu Huayu compound combined with antiviral therapy on peripheral blood lymphocyte subsets and inflammatory cytokines in patients with refractory chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 674-677.
[12]	Zhang Tingting, Wang Xuan.. What roles does dipeptidyl peptidase-4 play in chronic liver diseases? [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 637-640.
[13]	Zhang Guofan,Wang Fangfang,Guo Chunxia,et al.. Safety and efficacy of ascending doses interferon-α2b combined with ribavirin in treatment of patients with hepatitis-induced liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 345-346.
[14]	Su Shaohui，Hu Yiting，Hou Hongtao，et al.. Clinical characteristics of patients with human parvovirus B19 infection：An analysis of 17 cases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 364-366.
[15]	Ji Xiaoqin, Li Lei. Heme oxygenase-1 in the pathogenesis of chronic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 321-324.